Halozyme Therapeutics (HALO)$68.32
Market Cap: 7.49 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Halozyme Therapeutics (HALO).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
14.7x
EV/FCF, 6.8% FCF yield
Quality
14.5%
ROIC, 46.2% FCF margin
Growth
39.2%
5Y sales (revenue) CAGR
Balance sheet
43.9x
Debt/equity, 4.7x current ratio
Superinvestors
2
Top: Torray Funds (0.4%)
Strengths to research
- Revenue compounded at 39.2% over five years.
- Free cash flow compounded at 64.8% over five years.
- Return on equity is strong at 649.2%.
- Free cash flow margin is healthy at 46.2%.
Watchouts
- Debt/equity is high at 43.9x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for HALO.
Grade C
62
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| HALO Target | Halozyme Therapeutics | $7.5B | 26.7x | 14.7x | 14.5% | 39.2% | 46.2% | N/A | 4.2x | N/A |
| BBIO | BridgeBio Pharma Inc. | $7.3B | -18.3x | -19.5x | N/A | 127.4% | -89.0% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| LEGN | Legend Biotech Corp. | $6.1B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| AXSM | Axsome Therapeutics Inc. | $5.7B | -64.1x | -57.1x | -207.5% | N/A | -14.7% | N/A | N/A | N/A |
| IONS | Ionis Pharmaceuticals Inc. | $5.4B | -31.7x | -21.2x | -16.6% | 5.3% | -33.9% | N/A | N/A | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
Financial Charts
No financial data available for HALO (annual).
2 superinvestors own HALO
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Torray Funds Torray Funds | 38,179 | $2M | 0.39% | 0.0% |
| Richard Pzena Hancock Classic Value | 4,049 | $262,000 | 0.00% | 0.0% |